Professor Jonathan Wall and his team at the UT Graduate School of Medicine have spent more than two decades investigating systemic amyloidosis. Their work played an integral role in helping launch the biopharmaceutical company Attralus with technology licensed from UTRF. Today, Attralus announced that it has secured $25 million in investment financing to work on (read more)
License Agreement
Path to Market: New License for a UTIA Technology to a Fight Billion-Dollar Agricultural Crisis
Obtaining a commercial license with an industry partner doesn’t happen overnight. The journey of bringing a technology from initial discovery to the marketplace can be a long and challenging process. Industry landscape changes constantly, and companies consistently raise the bar on the amount of data and de-risking they require prior to licensing. Commercialization occurs in (read more)
Discover 2019: UTRF Annual Report
UTRF is delighted to share Discover 2019, which celebrates our researchers and UTRF’s impact on innovation, new venture formation, and corporate engagement for the University of Tennessee. 2019 UTRF Discover Report (interactive pdf with hyperlinks) View past annual reports.